Platine, Avastin and OLAparib in 1st Line (PAOLA-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02477644

Recruitment Status : Active, not recruiting

First Posted : June 23, 2015

Last Update Posted : January 21, 2020

Sponsor:

Collaborators:

Arbeitsgemeinschaft Gynaekologishe Onkologie Germany

Arbeitsgemeinschaft Gynaekologische Onkologie Austria

Grupo Español de Investigación en Cáncer de Ovario

Belgian Gynaecological Oncology Group

Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies

Mario Negri Gynecologic Oncology group (MaNGO)

Nordic Society for Gynaecologic Oncology

Gynecologic Oncology Trial & Investigation Consortium

Information provided by (Responsible Party):

Arcagy Research

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	March 22, 2019
Estimated Study Completion Date :	June 2022

Publications of Results:

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361.

To Top